UBS Group’s 10x Genomics TXG Stock Holding History

UBS Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$893K	–	8420
2020 Q2	$893K	Buy	+10,000	New	+$779K	﹤0.01%	3609

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's TXG Position: Q2 2026 in Review

UBS Group increased its 10x Genomics (TXG) stake by 0.02% in Q2 2026, buying an estimated $2.78K and bringing the position to 494,868 shares worth $19M. The position accounts for ﹤0.01% of the portfolio, ranked #2742.

UBS Group first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

UBS Group held 494,868 shares of 10x Genomics worth $19M as of Q2 2026.
UBS Group bought 106 10x Genomics shares in Q2 2026, an estimated $2.78K.
10x Genomics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2742 holding.
UBS Group first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.